Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 1
2007 1
2008 3
2010 6
2011 10
2012 16
2013 22
2014 29
2015 26
2016 23
2017 23
2018 11
2019 12
2020 12
2021 16
2022 11
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Results by year

Filters applied: . Clear all
Page 1
FGF receptors: cancer biology and therapeutics.
Katoh M, Nakagama H. Katoh M, et al. Med Res Rev. 2014 Mar;34(2):280-300. doi: 10.1002/med.21288. Epub 2013 May 21. Med Res Rev. 2014. PMID: 23696246 Review.
Missense mutations of FGFR2 are found in endometrial uterine cancer and melanoma, and similar FGFR3 mutations in invasive bladder tumors, and FGFR4 mutations in rhabdomyosarcoma. Dovitinib, Ki23057, ponatinib, and AZD4547 are orally bioavailable FGFR inhibitors, which have …
Missense mutations of FGFR2 are found in endometrial uterine cancer and melanoma, and similar FGFR3 mutations in invasive bladder tumors, an …
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M. Katoh M. Int J Mol Med. 2016 Jul;38(1):3-15. doi: 10.3892/ijmm.2016.2620. Epub 2016 May 31. Int J Mol Med. 2016. PMID: 27245147 Free PMC article. Review.
BCR-FGFR1, CNTRL-FGFR1, CUX1-FGFR1, FGFR1OP-FGFR1, MYO18A-FGFR1 and ZMYM2-FGFR1 fusions in myeloproliferative neoplasms are non-receptor-type FGFR kinases, whereas FGFR1-TACC1, FGFR2-AFF3, FGFR2-BICC1, FGFR2-PPHLN1, FGFR3-BAIAP2L1 and FGFR3-TACC3 fusions in solid tumors are trans …
BCR-FGFR1, CNTRL-FGFR1, CUX1-FGFR1, FGFR1OP-FGFR1, MYO18A-FGFR1 and ZMYM2-FGFR1 fusions in myeloproliferative neoplasms are non-receptor-typ …
A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro.
Lee Y, Bae KJ, Chon HJ, Kim SH, Kim SA, Kim J. Lee Y, et al. Mol Cells. 2016 May 31;39(5):389-94. doi: 10.14348/molcells.2016.2300. Epub 2016 Mar 30. Mol Cells. 2016. PMID: 27025387 Free PMC article.
Dovitinib enhanced the BMP-2-induced alkaline phosphatase (ALP) induction, which is a representative marker of osteoblast differentiation. ...In addition, the mRNA expression of BMP-4, BMP-7, ALP, and OCN increased with dovitinib treatment. Our results suggest that …
Dovitinib enhanced the BMP-2-induced alkaline phosphatase (ALP) induction, which is a representative marker of osteoblast differentia …
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.
Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A. Joensuu H, et al. Br J Cancer. 2017 Oct 24;117(9):1278-1285. doi: 10.1038/bjc.2017.290. Epub 2017 Aug 29. Br J Cancer. 2017. PMID: 28850565 Free PMC article. Clinical Trial.
BACKGROUND: This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. ...Tumour assessment and response …
BACKGROUND: This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of pat …
Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling.
Cao LL, Lu H, Soutto M, Bhat N, Chen Z, Peng D, Gomaa A, Wang JB, Xie JW, Li P, Zheng CH, Nomura S, Datta J, Merchant N, Chen ZB, Villarino A, Zaika A, Huang CM, El-Rifai W. Cao LL, et al. Gut. 2023 Nov;72(11):2038-2050. doi: 10.1136/gutjnl-2022-329134. Epub 2023 Jul 4. Gut. 2023. PMID: 37402563
Our analysis further identified a panel of RTKs as potential druggable targets in the immune desert-type GC. Dovitinib, an inhibitor of multiple RTKs, strikingly repressed EMT programming in mesenchymal-like immune desert syngeneic GC models. Dovitinib activated the …
Our analysis further identified a panel of RTKs as potential druggable targets in the immune desert-type GC. Dovitinib, an inhibitor …
Tyrosine kinase inhibitor TKI-258 inhibits cell motility in oral squamous cell carcinoma in vitro.
Carneiro ACDM, Silveira ICD, Rezende AS, Silva BRO, Crema VO. Carneiro ACDM, et al. J Oral Pathol Med. 2017 Aug;46(7):484-488. doi: 10.1111/jop.12511. Epub 2016 Oct 28. J Oral Pathol Med. 2017. PMID: 27732737
TKI-258 (1, 5, and 10 muM) treatment inhibits migrating cells (ANOVA, F = 97.749, d.f. = 3, 10; P < 0.0001), and it was concentration dependent. Invading cell treated with 5 muM TKI-258 was significantly lower (t = 6.708, d.f. = 5, P < 0.001). .. …
TKI-258 (1, 5, and 10 muM) treatment inhibits migrating cells (ANOVA, F = 97.749, d.f. = 3, 10; P < 0.0001), and it was con …
Activation of the integrated stress response by inhibitors of its kinases.
Szaruga M, Janssen DA, de Miguel C, Hodgson G, Fatalska A, Pitera AP, Andreeva A, Bertolotti A. Szaruga M, et al. Nat Commun. 2023 Sep 8;14(1):5535. doi: 10.1038/s41467-023-40823-8. Nat Commun. 2023. PMID: 37684277 Free PMC article.
Reconstitution of ISR activation with recombinant proteins demonstrates that PERK and PKR inhibitors directly activate dimeric GCN2, following a Gaussian activation-inhibition curve, with activation driven by allosterically increasing GCN2 affinity for ATP. The tyrosine kinase in …
Reconstitution of ISR activation with recombinant proteins demonstrates that PERK and PKR inhibitors directly activate dimeric GCN2, followi …
Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications.
Yadav SS, Li J, Stockert JA, Herzog B, O'Connor J, Garzon-Manco L, Parsons R, Tewari AK, Yadav KK. Yadav SS, et al. Transl Oncol. 2017 Jun;10(3):357-366. doi: 10.1016/j.tranon.2017.01.011. Epub 2017 Mar 24. Transl Oncol. 2017. PMID: 28342996 Free PMC article.
This, along with previous observations of an increase in the number of such NE cells in aggressive tumors, has been suggested as a mechanism of resistance development during prostate cancer progression. Dovitinib (TKI-258/CHIR-258) is a pan receptor tyrosine …
This, along with previous observations of an increase in the number of such NE cells in aggressive tumors, has been suggested as a mechanism …
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL, Wong CH, Lau CP, Zhou Q, Hui CW, Lui VW, Ma BB, Chan AT, Yeo W. Chan SL, et al. Cancer Chemother Pharmacol. 2013 Jun;71(6):1417-25. doi: 10.1007/s00280-013-2139-4. Epub 2013 Apr 2. Cancer Chemother Pharmacol. 2013. PMID: 23546591
We aim to study the activity of combined RAD001 and TKI-258 in cell lines and xenograft model of hepatocellular carcinoma (HCC), with reference to the parallel and upstream pathways of Akt-mTOR axis. ...RESULTS: There was an enhanced increase in suppression of cell …
We aim to study the activity of combined RAD001 and TKI-258 in cell lines and xenograft model of hepatocellular carcinoma (HCC …
Preformulation studies of dovitinib free base: Solubility, lipophilicity and stability.
Sripetch S, Ryzhakov A, Loftsson T. Sripetch S, et al. Int J Pharm. 2022 May 10;619:121721. doi: 10.1016/j.ijpharm.2022.121721. Epub 2022 Apr 6. Int J Pharm. 2022. PMID: 35398252
Dovitinib free base has a poor water solubility leading to poor absorption. ...Aqueous solubility of dovitinib salt depended on the counterion. Lactic acid greatly increased the aqueous solubility of dovitinib. ...
Dovitinib free base has a poor water solubility leading to poor absorption. ...Aqueous solubility of dovitinib salt depended o …
213 results